- Home
- DBD vs VCEL Comparison
DBD vs VCEL Comparison
Compare DBD & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | VCEL |
|---|---|---|
| Founded | 1859 | 1989 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DBD | VCEL |
|---|---|---|
| Price | $71.68 | $44.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $90.00 | $57.75 |
| AVG Volume (30 Days) | 278.8K | ★ 463.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | 60.00 |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $3,805,700,000.00 | $276,259,000.00 |
| Revenue This Year | $3.56 | $19.40 |
| Revenue Next Year | $3.25 | $18.24 |
| P/E Ratio | $124.61 | ★ N/A |
| Revenue Growth | 1.46 | ★ 16.45 |
| 52 Week Low | $54.48 | $28.95 |
| 52 Week High | $92.09 | $49.32 |
Technical Indicators
Market Signals| Indicator | DBD | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 49.50 |
| Support Level | $70.35 | $44.26 |
| Resistance Level | $85.98 | $49.04 |
| Average True Range (ATR) | 3.93 | 1.49 |
| MACD | -1.20 | -0.45 |
| Stochastic Oscillator | 5.62 | 28.36 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.